Novartis’ acquisition of U.S.-based Excellergy will add an early-stage drug candidate Exl-111 to the company’s existing allergy portfolio. It comes just a week after Novartis announced it is acquiring Synnovation subsidiary Pika... Read more
Energy news aggregation website, sourcing the latest energy news from reputable sources across the web.
















